glp-1 prostate cancer May Patients Receiving Agonists Be at Lower Risk of Aggressiveness and Progression? Glucagon‐like peptide‐1 receptor (GLP‐1R) expression

This article is part of the PlexusDx Education Hub your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision

Those looking to boost metabolism and burn fat efficiently

The medication is a tool, not a replacement for good nutrition

Hims claims that it can sell unapproved versions of semaglutide because its drugs are compounded by outsourcing facilities and not manufactured by drug companies. Federal law constrains the making of compounded products to very narrow circumstances, intended to be a limited exception from the general rule that pharmaceutical products must meet rigorous standards of demonstrated safety and efficacy before they can be approved by FDA and prescribed to patients

Serious side effects are rare when administered by professionals.